Abstract

To expand its marketed and pipeline product portfolio, Alcon entered into an agreement to acquire the rights to two products, Durezol™ (difluprednate ophthalmic emulsion) and Zirgan™ (ganiciclovir ophthalmic gel) from Sirion Therapeutics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login on the top right purple box.

Copyright: PharmaVentures Ltd